Form 4: MoonLake Immunotherapeutics Director Acquires Options
SEC Form 4
Director Simon Sturge acquired options to purchase 7,688 Class A ordinary shares of MoonLake Immunotherapeutics on June 6, 2024.
Summary
- On June 6, 2024, Simon Sturge, a director of MoonLake Immunotherapeutics, acquired options to buy 7,688 Class A ordinary shares.
- The exercise price of the options is $42.44.
- The options vest on the earlier of June 6, 2025, the date of the next annual general meeting, or a change in control, contingent on continued service to the Issuer.
- The options expire on June 6, 2034.
Sentiment
Score: 5
Explanation: This is a routine disclosure of an option grant, neither particularly positive nor negative.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Option grants are a common form of executive compensation in the biotechnology industry.
Stakeholder Impact
- The option grant aligns the director's interests with those of the shareholders, incentivizing him to increase the company's value.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of the option acquisition. |
| 06/06/2025 | Earliest vesting date for the options. |
| 06/06/2034 | Expiration date of the options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.